ERBB2 and triple-negative breast carcinoma: Approximately 10% of all triple-negative breast cancer (TNBC) patients carry gBRCA PVs [3–5], while ~9% belong to human epidermal growth factor receptor 2 (HER2)-negative BC patients [5].